Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Attractive market fundamentals | Leadership and scale | Multiple growth drivers | Margin improvement | Attractive financial outlook Compelling sustainability story
2023 and mid-term guidance
Sales growth1
%
Core EBITDA
% margin
Dividend policy
% of core net income
2023 guidance
Mid-term guidance (2028E)
Mid-single digit
Mid-single digit
-18-19%
20-30%
Full year dividend based on
FY 2023 core net income
-24-26%
30-40%
Note: Unless the context requires otherwise, the expression "mid-term" used in this section refers to a forecast until 2028. As with any projection or forecast, these five-year outlook measures are inherently susceptible to uncertainty and are based on
various assumptions that may turn out to be incorrect. For additional information regarding core results and constant currencies, which are non-IFRS measures, see "Appendix" starting on slide 31; 1. Net sales to third parties, in constant currencies
Management Presentation
27
SANDOZView entire presentation